Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms

Overview

This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients with NALP3 mutations whose clinical symptoms are either untreated or insufficiently treated and require medical intervention.

Full Title of Study: “An Open-Label, Phase II Dose Titration Study of ACZ885 (Human Anti-IL-1β Monoclonal Antibody) to Assess the Clinical Efficacy, Safety, Pharmacokinetics and Pharmacodynamics in Patients With NALP3 Mutations”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 2008

Interventions

  • Drug: canakinumab

Arms, Groups and Cohorts

  • Experimental: 1
    • ACZ885

Clinical Trial Outcome Measures

Primary Measures

  • Response to treatment and time to relapse after ACZ885 administration according to monthly investigator’s clinical assessments, laboratory monitoring, and patient diaries.
    • Time Frame: Every month

Secondary Measures

  • Assessment of safety,tolerability and immunogenicity of ACZ885 at each clinical visit. Evaluation of ACZ885 PK and PD at each clinical visit Evaluate efficacy towards hearing loss(every 4 months),kidney function (every 4 months),neurological symptoms
    • Time Frame: Every month

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged 4 to 75 years (inclusive) – Body weight ≥ 12 kg and < 100 kg. – Females of child-bearing potential must have a negative pregnancy test. Additional birth control details to be provided at screening. – Documented molecular diagnosis of NALP3 mutations and clinical symptoms that are either untreated or insufficiently treated and require medical intervention. – Patients under anakinra therapy or any other IL-1 blocking therapy, whose clinical symptoms improved under treatment and are willing to discontinue that therapy until a relapse becomes evident. – Patients with a very severe characteristics requiring oral prednisone are eligible if the dose is stable (≤ 0.4 mg/kg/day or ≤ 20 mg/day, whichever is lower) for at least 1 week prior to the screening visit. Steroid therapy may be tapered during treatment with ACZ885 at the discretion of the investigator. – Parents' or legal guardian's written informed consent (patient's informed consent for ≥ 18 years of age) and child's assent, if appropriate, are required prior to study participation. Exclusion Criteria:
  • Participation in any clinical trial investigation (except trials with anakinra) within 4 weeks prior to dosing or longer per local regulation – Antiinflammatory therapy with colchicine, chlorambucil, dapsone, azathioprine, mycophenolate mofetil, within 3 weeks prior to dosing. Therapeutic antibodies (e.g. anti-TNF-alpha antibodies) must be discontinued at least 60 days before dosing. – Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing. – A past personal or close family medical history of clinically significant ECG abnormalities or prolonged QT-interval syndrome. – History of – Immunocompromise, including a positive HIV result. – Positive Hepatitis B surface antigen or Hepatitis C test result. – Drug or alcohol abuse within the 12 months prior to dosing. – Tuberculosis. – Renal transplant. – Evidence of lymphoma. – Active medical condition preventing participation in the study such as infection, poorly controlled diabetes etc. – No live vaccinations within 3 months prior to the start of the trial, during the trial, and up to 3 months following the last dose.
  • Gender Eligibility: All

    Minimum Age: 4 Years

    Maximum Age: 75 Years

    Are Healthy Volunteers Accepted: No

    Investigator Details

    • Lead Sponsor
      • Novartis Pharmaceuticals
    • Provider of Information About this Clinical Study
      • External Affairs, Novartis Pharmaceuticals
    • Overall Official(s)
      • Novartis, Principal Investigator, Investigative site

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.